D-4Science and Technology and other Research and Development

DoW Toxic Exposures Clinical Trial Award

Agency: Department of Defense
Run by: Ebony S Simmons Grantor
Target applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Application period: 2026-05-21 ~ 2026-11-19
Contact: Ebony S Simmons Grantor 301-619-2105

Open in EDIT and start the application View on Grants.gov Application site

Source: Grants.gov

How to apply

Register your organization on SAM.gov to get a UEI (Unique Entity ID). It can take up to 10 business days to become active, and it must be renewed every year. SAM.gov
Create a Grants.gov account and add an applicant profile with your UEI. The E-Business Point of Contact named in SAM.gov gives the person who submits the AOR role. Grants.gov
On the opportunity page, select Apply to create a Workspace. Complete the SF-424 and the other required forms in Workspace. Opportunity page
Attach the narrative documents the NOFO asks for (such as the Project Narrative, Project Abstract and Budget Justification) in Workspace. EDIT can draft them from your materials. Workspace
Submit from Workspace, then check the status with your Grants.gov tracking number. Track my application

Overview

Summary: The fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Clinical Trial Award (CTA) mechanism supports the advancement, execution, and analysis of clinical trials with the potential to have a significant impact on the prevention, treatment, or management of symptoms, diseases or conditions associated with or resulting from military-related toxic exposures. Proposed projects may range from small proof-of-concept clinical trials (e.g., pilot, first-in-human, phase 0) designed to demonstrate the feasibility or inform the design of more advanced trials, through large-scale trials (including pragmatic clinical trials) to determine efficacy in relevant patient populations. Distinctive Features: To encourage applications that include meaningful and productive collaborations, the FY26 TERP CTA includes a Partnering Principal Investigator Option (PPIO). One Principal Investigator (PI) is identified as the initiating PI, and an additional PI may be identified as a Partnering PI. If recommended for funding, each PI will be named on separate awards. The intent is to support interdisciplinary partnerships, such as those between clinicians and research scientists, that will accelerate the movement of promising interventions/knowledge products into clinical applications. Partnering should significantly advance the research beyond what would be possible through independent efforts. https://cdmrp.health.mil/pubs/press/2026/terppreann Estimated total funding: $4,500,000 Expected awards: 1 Opportunity number: HT942526TERPCTA